Hypocalcemia is one of the cardinal features of the chromosome 22q11.2 deletion syndrome (22q11.2DS), the most common cause of DiGeorge syndrome. Hypocalcemia and other features of 22q11.2DS including congenital heart disease (CHD) are primarily ascribed to problems with morphogenesis and function of the pharyngeal arch system derivatives including the parathyroid glands, the aortic arch, and the cardiac outflow tract. In light of the aforementioned embryology, we hypothesized that hypocalcemia would be identified more frequently in those patients with 22q11.2DS and CHD. We conducted a retrospective IRB approved chart review on 1,300 subjects with 22q11.2DS evaluated at the Children's Hospital of Philadelphia. χ 2 test was used to evaluate the statistical significance of differences in hypocalcemia between the two groups.
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Eight hundred fifty-two patients had calcium levels available for review. Of these, 466 (54.69%) had a history of hypocalcemia and 550 (64.55%) had CHD. Of those with CHD, 343 (62.36%) had a history of hypocalcemia, and of those without CHD, only 123 (40.73%) had a history of hypocalcemia. Thus, the frequency of diagnosed hypocalcemia was greater in patients with 22q11.2DS and CHD as compared to those without CHD (p < .001). We also analyzed age of onset of hypocalcemia and found that 66.47% of CHD/hypocalcemia group had neonatal/infantile hypocalcemia versus 43.09% in the non-CHD/hypocalcemia group. In our large cohort of patients with 22q11.2DS, the prevalence of diagnosed hypocalcemia is elevated among patients with CHD, in whom it is more likely to be diagnosed during the neonatal/infancy period.
Microdeletion of chromosome 22q11.2 results in maldevelopment of the third and fourth pharyngeal pouches and is the most common interstitial deletion syndrome, affecting 1/2,000-6,000 live births and 1/1,000 unselected fetuses (Botto et al., 2003; Grati, Gomes, Ferreira, & Dupont, 2015) . Cardinal features of this condition include congenital heart disease (CHD), hypoparathyroidism, immunodeficiency, palatal abnormalities, gastrointestinal differences, renal anomalies, developmental differences, and psychiatric illness (McDonald-McGinn, 2015) . CHD is the most common cause of mortality in this syndrome (McDonaldMcGinn, 2001 ).
Endocrinopathies are also frequent in 22q11.2DS, with hypoparathyroidism being the most common (Choi et al., 2005) . Hypocalcemia is reported in approximately 50%-69% of patients with 22q11.2DS
and is caused by agenesis or hypoplasia of the parathyroid glands, which are derivatives of the third and fourth pharyngeal pouches (Weinzimer, 2001) . Hypoparathyroidism in this condition generally seems to be a result of decreased PTH reserve, with a predisposition to develop hypocalcemia during periods of stress or illness (Kapadia, Kim, McDonald-McGinn, Zackai, & Levitt Katz, 2008) . Other endocrine manifestations include hypothyroidism, Graves' disease, and growth hormone deficiency (Choi et al., 2005) . Additionally, the presence/absence of CHD was also recorded and correlated with the presence/absence of history of hypocalcemia.
χ 2 test was used to evaluate the statistical significance of differences in hypocalcemia between the two groups.
| RESULTS
Of the 852 patients with 22q11.2DS and Ca evaluations, there were an equal number of males and females. Patients ranged from 6 months to 59 years at time of Ca measurement ( Table 1) . The majority of patients (n = 798) had a typical LCR22A-LCR22D deletion (93.66%), whereas 54 had atypical nested deletions (6.34%) ( Table 2 ). The overall prevalence of hypocalcemia was 54.69% (n = 466) while 45.31%
(n = 386) were normocalcemic, consistent with prior literature. The overall calcium values ranged between 7.3 and 9.9 with an average Ca level of 9.0 and a standard deviation of 0.488. In patients with multiple Ca levels, the median value for each patient was used to calculate the average. Neonatal and infantile hypocalcemia (defined as occurring within the first month and between the first month and first year of life, respectively) were noted most frequently in the hypocalcemia group. However, importantly 20.82% of patients developed hypocalcemia in childhood and 13.95% during adolescence and adulthood for the first time (Table 3) .
CHD was present in 550 of 852 patients (64.55%) including:
Tetralogy of Fallot (25%), ventricular septal defect (21%), interrupted aortic arch (15%), other aortic arch abnormality (12%), truncus arteriosus (8%), atrial septal defect (7%), and vascular ring (4%). Forty-three of 852 patients, ages 0.5-58 years, had no CHD status recorded in the database and were included in the non-CHD group, given they had no evidence of cardiac evaluation or intervention in their charts.
In an effort to assess the relationship between comorbidities, we compared the presence of hypocalcemia in the 852 patients with the presence/absence of CHD. Three hundred forty-three of 550 (62.36%) patients with CHD had findings of hypocalcemia while 123 of 302 (40.73%) patients without known CHD had hypocalcemia.
Thus, the frequency of hypocalcemia is statistically significantly higher in patients with CHD with a chi squared of 36.8 (p < .0001) as compared to those without a CHD. As noted in Table 4 , there is a higher prevalence of hypocalcemia in severe heart disease when compared Additionally, among those patients with CHD and hypocalcemia, the majority had their first episode of hypocalcemia in the neonatal period and infancy, as seen in Table 5 . Among patients with hypocalcemia, 66.47% of the CHD group had hypocalcemia diagnosed before 1 year of age versus 43.09% of the non-CHD group.
| DISCUSSION
In this large cohort of patients (N = 852) with 22q11.2DS, we found a history of hypocalcemia was present in 54.69% of our patients. Moreover, hypocalcemia was more often present in those patients with CHD and was more likely diagnosed in the neonatal period and infancy. This frequency is slightly higher than the previous reports from smaller populations. In fact, even within our own center, we previously reported a slightly lower prevalence of hypocalcemia (49%) in a subset of our cohort (N = 158 patients) (McDonald-McGinn et al., 1999) . In a larger European multicenter combined cohort of 558 patients with 22q11.2 deletions (Ryan et al., 1997) , 340 patients had calcium levels reported, of which 60% were found to have hypocalcemia most often in the neonatal period, although some occurred during childhood, and one patient had onset at 18 years of age.
Congenital heart disease (CHD) was present in 64.55% of our 852 patients. Previously at our center, which sees a large number of referrals for cardiac surgery, CHD was reported to be present in 74% LCR22A-LCR22B (n = 27) 14 13
LCR22A-LCR22C (n = 6) 5 1 LCR22B-LCR22D (n = 13) 2 11 LCR22C-LCR22D (n = 6) 3 3 LCR22C-LCR22E (n = 1) 0 1 LCR22D-LCR22E (n = 1) 0 1 of extracardiac anomalies were similar in both groups. Patients with 22q11.2DS are at a higher risk for complications and hypocalcemia may be a contributor to the differences noted above. The differences may also be a result of infection as a result of immunodeficiency (Sullivan, 2004 ) but this was not noted in this study by Mercer-Rosa et al.
In a small study of 22 patients with 22q11.2DS/CHD and 110 patients with only CHD, postoperative hypocalcemia was observed in 86.4% of patients with 22q11.2DS compared to 47.3% of patients without a deletion-a statistically significant difference (Shen et al., 2011) . In the nondeletion subjects, hypocalcemia was usually seen at cardiopulmonary bypass initiation, after which they quickly recovered, likely due to a subsequent increase in parathyroid hormone through appropriate feedback mechanisms. However, in patients with 22q11.2DS, the ability to increase production/release of PTH is limited due to parathyroid gland abnormalities, therefore likely resulting in a higher prevalence and detection rate of hypocalcemia. Given these outcomes and the results of our current analysis, it is important to screen for 22q11.2DS in infants with CHD, and also to monitor calcium in patients with 22q11.2DS undergoing surgery and postoperatively. Moreover, as hypocalcemia can complicate intraoperative management, it is also a contributor to protracted postoperative recovery.
Given that our study was a retrospective chart review of large sample size, a major limitation of our study is that we were unable to obtain specifics on recurrence/follow-up of hypocalcemia. Another limitation of our study includes lack of PTH levels obtained with hypocalcemia to confirm the presence of hypoparathyroidism. It is possible that the some of the hypocalcemia may be related in part to surgery/ postoperative factors in the intensive care setting that are unrelated to embryologic parathyroid gland abnormalities. Additionally, the hypocalcemia may be misleading in the setting of hypoalbuminemia that may occur in the postop setting, in the first few days of life in which there is a physiological nadir of serum calcium, which can be exaggerated leading to frank transient hypocalcemia in premature infants and infants of diabetic mothers.
While we did find that the more severe congenital heart disease (Tetralogy of Fallot, interrupted aortic arch, truncus arteriosus) was associated with higher frequency of patients having a history of hypocalcemia, we are unable to tell if this is a result of stress of surgery in the neonatal period or even a selection bias of those that were headed to the OR and had labs ordered. In the study by Shen et al. cited above, nondeletion patients undergoing cardiac surgery were also found to have hypocalcemia. A control population of patients with CHD would be helpful in delineating the frequency of hypocalcemia in patients with isolated CHD without 22q11.2DS compared to those with 22q11.2DS.
In conclusion, in a large cohort of patients with 22q11.2DS, we found a significant association of a history of hypocalcemia with CHD, more often diagnosed in the neonatal period and infancy. Because of the high volume of cardiac surgery performed at our institution, our findings may relate to early identification of younger patients with hypocalcemia in association with CHD during neonatal hospitalization.
This speaks to the importance of early diagnosis of 22q11.2DS, in particular as a cause of CHD. Therefore, identification of CHD and hypocalcemia, should prompt us to think about and to test for 22q11.2 DS.
